Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...
with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...
The amelioration of the B cell immunity signature across diverse treatments emphasises the key role of B cells in the pathogenesis of SLE through autoantibody production and antibody-independent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback